内科

目的探讨弥漫大B细胞淋巴瘤（DLBCL）患者血清血管内皮生长因子（VEGF）、碱性成纤维细胞生长因子（bFGF）的水平及临床意义。方法选取2019年2月至2020年2月我院收治的DLBCL患者140例及同期在我院进行体检的健康者70例为研究对象。采用环磷酰胺+阿霉素+长春新碱+泼尼松（CHOP）方案对患者进行化疗。比较DLBCL患者（治疗前）与健康者的血清VEGF、bFGF水平；比较不同临床分期DLBCL患者治疗前、治疗 1个疗程后的血清VEGF、bFGF水平；比较治疗1个疗程后不同临床转归DLBCL患者的血清VEGF、bFGF水平及淋巴瘤国际预后指数（IPI）评分；对DLBCL患者治疗前的血清VEGF、bFGF水平与IPI评分的关系进行Pearson相关性分析。结果治疗前DLBCL患者的血清VEGF、bFGF水平均显著高于健康者，差异有统计学意义（P＜0.05）。不同临床分期DLBCL患者的血清VEGF、bFGF水平比较差异有统计学意义，临床分期越高的患者治疗后其VEGF、bFGF水平的下降幅度越大（P＜0.05）。治疗前、治疗1个疗程后，好转与恶化DLBCL患者的血清VEGF水平、bFGF水平、IPI评分比较差异有统计学意义，治疗后好转患者的血清VEGF水平、bFGF水平、IPI评分的降幅显著大于恶化患者（P＜0.05）。Pearson相关性分析结果显示，DLBCL患者治疗前的血清VEGF、bFGF水平与其IPI评分均呈正相关。结论弥漫大B细胞淋巴瘤患者的血清VEGF、bFGF水平显著高于健康者，化疗后显著降低；患者的VEGF、bFGF水平与其治疗效果、病情、肿瘤侵袭情况等均存在较为密切的关系，对判断患者的病情、治疗效果及预后具有重要的临床意义。

ObjectiveTo explore the levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with diffuse large B-cell lymphoma (DLBCL) and their clinical significance. MethodsA total of 140 DLBCL patients admitted to our hospital from February 2019 to February 2020 and 70 healthy people who underwent physical examination in our hospital during the same period were selected as the research objects. The chemotherapy was conducted on patients using the regimen of cyclophosphamide + adriamycin + vincristine + prednisone (CHOP). The pre-treatment serum levels of VEGF and bFGF between the DLBCL patients and healthy people, the levels mentioned above before treatment and after 1 treatment course between the DLBCL patients in different clinical stages, and the levels as above and the scores of the International Prognostic Index (IPI) for lymphoma after 1 treatment course between the DLBCL patients with different clinical outcomes were compared. The Pearson correlation analysis was performed on the relationship between pre-treatment serum VEGF, bFGF levels and IPI scores of DLBCL patients. ResultsThe serum VEGF and bFGF levels of the DLBCL patients before treatment were significantly higher than those of the healthy people, and the differences were statistically significant (P＜0.05). There were statistically significant differences in serum VEGF and bFGF levels of DLBCL patients in different clinical stages. The higher the clinical stage was, the greater range of the post-treatment levels of VEGF and bFGF decreased (P＜0.05). There were statistically significant differences in the levels of serum VEGF and bFGF, and IPI scores between improved and deteriorated DLBCL patients before treatment and after 1 course of treatment. The serum VEGF and bFGF levels and IPI scores of the improved patients after treatment decreased significantly than those of the deteriorated patients (P＜0.05). The results of Pearson correlation analysis showed that the serum VEGF and bFGF levels of DLBCL patients before treatment were positively correlated with their IPI scores. ConclusionThe serum VEGF and bFGF levels of the patients with diffuse large B-cell lymphoma were significantly higher than those of the healthy people, and the levels significantly decreased after chemotherapy. The levels of VEGF and bFGF of patients are closely related to their curative effects, disease conditions, tumor invasion, etc., which are of clinical significance for judging the conditions, treatment effects, and prognosis in patients.